Related Experiment Videos
Early oral cysteamine therapy for nephropathic cystinosis
1Section on Human Biochemical Genetics, National Institute of Child Health and Human Development, National Institutes of Health, MSC 1851 Building 10, Room 10C-103, 10 Center Drive, Bethesda, Maryland 20892-1851, USA. bgahl@helix.nih.gov
Insights
Early diagnosis and treatment of nephropathic cystinosis, a rare genetic disorder, can significantly alter its course. Prompt intervention with cysteamine therapy preserves kidney function and promotes healthy growth in affected children.
Area of Science:
- Genetics and Metabolic Disorders
- Lysosomal Storage Diseases
- Pediatric Nephrology
Background:
- Nephropathic cystinosis is a genetic disorder causing cystine buildup in lysosomes.
- It leads to Fanconi syndrome, growth failure, hypothyroidism, and kidney damage by age 10.
- Mutations in the CTNS gene, particularly a large deletion, are implicated.
Purpose of the Study:
- To summarize the clinical manifestations and genetic basis of nephropathic cystinosis.
- To highlight the efficacy of cysteamine therapy in managing the disease.
- To emphasize the critical role of early diagnosis and intervention.
Main Methods:
- Review of clinical manifestations and genetic mutations associated with nephropathic cystinosis.
- Analysis of the therapeutic effects of oral cysteamine (Cystagon).
- Discussion of the impact of early diagnosis through newborn screening.
Main Results:
- Oral cysteamine effectively reduces intracellular cystine levels and mitigates disease progression.
- Early cysteamine treatment preserves renal function and supports normal growth and development.
- Newborn screening for CTNS mutations enables timely diagnosis and treatment initiation.
Conclusions:
- Early detection and prompt treatment of nephropathic cystinosis are crucial for improving patient outcomes.
- Aggressive cysteamine therapy can significantly alter the disease's natural course, preventing severe complications.
- Newborn screening holds promise for identifying affected infants within the critical early treatment window.
Unlabelled:
Nephropathic cystinosis is an autosomal recessive lysosomal storage disorder in which intracellular cystine accumulates due to impaired transport out of lysosomes. The clinical manifestations include renal tubular Fanconi syndrome in the 1st year of life, with hypophosphatemic rickets, hypokalemia, polyuria, dehydration and acidosis, growth retardation, hypothyroidism, photophobia, renal glomerular deterioration by 10 years of age, and late complications such as myopathy, pancreatic insufficiency, and retinal blindnesss. The cystinosis gene, CTNS, codes for cystinosin, a 367 amino acid protein with seven transmembrane domains. More than 50 CTNSmutations have been identified, but approximately 50% of Northern European patients have a 57257-bp deletion which removes the first nine exons of CTNS. The mainstay of cystinosis therapy is oral cysteamine (Cystagon). This aminothiol can lower intracellular cystine content by 95%, and has proven efficacy in delaying renal glomerular deterioration, enhancing growth, preventing hypothyroidism, and lowering muscle cystine content. Its early and diligent use is critical; in one study, for every month of treatment prior to 3 years of age, 14 months' worth of later renal function were preserved. Several examples of individual patients treated early and having preserved renal function and normal growth are available. Newborn screening using a chip containing cDNA to detect common CTNSmutations may allow diagnosis and treatment in the first weeks of life.
Conclusions:
Early diagnosis and treatment of nephropathic cystinosis can change the course of this disease.